Antidiabetic medication may modify the incidence of hepatocellular carcinoma (HCC). We
aimed to compare the use of different antidiabetic strategies and the incidence of HCC …

Several preclinical and observational studies have shown that anti-diabetic medications
(ADMs) can modify the risk of hepatocellular cancer (HCC) in patients with diabetes mellitus …

Preventive effect of metformin in hepatocellular carcinoma (HCC) is not entirely clear. We
aimed to evaluate the use of metformin as a protective factor of HCC in diabetic patients.. We …

Background The views regarding the associations between metformin use and
hepatocellular carcinoma (HCC) among diabetes mellitus (DM) patients are divisive. Thus …

Studies of diabetes and hepatocellular carcinoma (HCC) yielded inconsistent findings. This
meta‐analysis was conducted to examine the association between diabetes and risk of …

Objectives. Recent epidemiological studies suggest that metformin treatment may reduce
the risks of cancer and overall cancer mortality among patients with diabetes mellitus (DM) …

Introduction. Metabolic conditions, including type 2 diabetes, have been related to
hepatocellular carcinoma (HCC) risk. We have further analyzed the role of diabetes and …

Context: Data on the potential effect of metformin on the risk of liver cancer are limited and
inconsistent. Objective: The objective of this study was to review the evidence currently …

Questions remain about the relationship between type 2 diabetes mellitus (type 2 DM) and
the risk of hepatocellular carcinoma (HCC), especially in patients with chronic liver diseases …

In recent years, increasing evidence has suggested a strong association between diabetes
mellitus (DM) and hepatocellular carcinoma (HCC). To provide a quantitative assessment of …